For example, the combination of T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) inhibitors with PD-1/PD-L1 inhibitors has shown significant synergy in hepatocellular carcinoma (HCC) (9). Here, HAVCR2 is linked to hepatocellular carcinoma.